Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep;29(9):2185-2186.
doi: 10.1038/s41591-023-02515-0.

Decoding antigen escape and multiple myeloma relapse after targeted immunotherapy

No authors listed
Comment

Decoding antigen escape and multiple myeloma relapse after targeted immunotherapy

No authors listed. Nat Med. 2023 Sep.
No abstract available

PubMed Disclaimer

Comment on

  • Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.
    Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, Landgren O, Walter W, Meggendorfer M, Haferlach C, Haferlach T, Einsele H, Kortüm MK, Knop S, Alberge JB, Rosenwald A, Keats JJ, Rasche L, Maura F, Neri P, Bahlis NJ. Lee H, et al. Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31. Nat Med. 2023. PMID: 37653344 Free PMC article.

References

    1. Zhou, X. et al. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica 108, 958–968 (2023). This review article summarizes the existing data on BCMA loss after immunotherapy in MM. - DOI - PubMed
    1. Leblay, N. et al. Cite-Seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR T or BiTES immunotherapy. Blood 136, 11–12 (2020). This conference abstract describes the emergence of TNFRSF17 biallelic deletion from pre-existing subclones with monoallelic TNFRSF17 deletion during progression after anti-BCMA CAR T cell therapy. - DOI
    1. Da Vià, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616–619 (2021). This study describes the selection of clones with homozygous TNFRSF17 deletion as an escape mechanism after anti-BCMA CAR T cell therapy and reports heterozygous TNFRSF17 loss or monosomy 16 as a potential risk factor for BCMA loss after targeted immunotherapy. - DOI - PubMed
    1. Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021). This research article associates BCMA antigen loss through TNFRSF17 monoallelic deletion and a truncating mutation after anti-BCMA CAR T cell therapy with lack of response to subsequent infusion of CAR T cells. - DOI - PubMed - PMC
    1. Truger, M. S. et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 5, 3794–3798 (2021). This research article reports that homozygous TNFRSF17 loss after anti-BCMA TCE therapy precluded a response to subsequent anti-BCMA therapies. - DOI - PubMed - PMC

LinkOut - more resources